Cargando…
Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors
Monoclonal antibodies (mAbs) are one of the cornerstones of modern medicine, across an increasing range of therapeutic areas. All therapeutic mAbs are glycoproteins, i.e., their polypeptide chain is decorated with glycans, oligosaccharides of extraordinary structural diversity. The presence, absence...
Autores principales: | Li, Shasha, McCraw, Alex J., Gardner, Richard A., Spencer, Daniel I.R., Karagiannis, Sophia N., Wagner, Gerd K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628514/ https://www.ncbi.nlm.nih.gov/pubmed/34842612 http://dx.doi.org/10.3390/antib10040044 |
Ejemplares similares
-
Generation and Characterization of Native and Sialic Acid-Deficient IgE
por: McCraw, Alex J., et al.
Publicado: (2022) -
Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development
por: Li, Wei, et al.
Publicado: (2017) -
A versatile design platform for glycoengineering therapeutic antibodies
por: Ludwig, Seth D., et al.
Publicado: (2022) -
Strategies for Glycoengineering Therapeutic Proteins
por: Dammen-Brower, Kris, et al.
Publicado: (2022) -
IgE Antibodies against Cancer: Efficacy and Safety
por: Chauhan, Jitesh, et al.
Publicado: (2020)